论文部分内容阅读
生物产业被列为“十二五”期间重点发展战略性新兴产业之一。在这期间,政府将在生物医药的重大新药研制及研发专项领域的资金投入达到400亿元,较“十一五”期间的178亿元高出124.72%。同时,随着人民可支配收入的提升及健康意识的改变,药品需求也有望继续提升。国内技术水准的提升,有望推动产业化,增加药品种类及供给,增加生物制药产业产值。
Biological industry was listed as one of the key emerging strategic industries during the 12th Five-Year Plan period. During this period, the government will invest 40 billion yuan in the major areas of biopharmaceutical research and R & D, 124.72% higher than the 17.8 billion yuan during the 11th Five-Year Plan period. At the same time, with the increase of disposable income and the change of health awareness, the demand for medicines is also expected to continue to rise. The improvement of domestic technical standards is expected to promote industrialization, increase the types and supply of medicines and increase the output value of the bio-pharmaceutical industry.